- Home
- SGLY vs PRTG Comparison
SGLY vs PRTG Comparison
Compare SGLY & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- PRTG
- Stock Information
- Founded
- SGLY 2001
- PRTG 1973
- Country
- SGLY United States
- PRTG British Virgin Islands
- Employees
- SGLY N/A
- PRTG N/A
- Industry
- SGLY
- PRTG Oil & Gas Production
- Sector
- SGLY
- PRTG Energy
- Exchange
- SGLY Nasdaq
- PRTG Nasdaq
- Market Cap
- SGLY 5.8M
- PRTG 4.7M
- IPO Year
- SGLY 2008
- PRTG N/A
- Fundamental
- Price
- SGLY $2.60
- PRTG $4.02
- Analyst Decision
- SGLY
- PRTG
- Analyst Count
- SGLY 0
- PRTG 0
- Target Price
- SGLY N/A
- PRTG N/A
- AVG Volume (30 Days)
- SGLY 115.1K
- PRTG 65.0K
- Earning Date
- SGLY 02-26-2025
- PRTG 02-26-2025
- Dividend Yield
- SGLY N/A
- PRTG N/A
- EPS Growth
- SGLY N/A
- PRTG N/A
- EPS
- SGLY N/A
- PRTG N/A
- Revenue
- SGLY $2,742,157.00
- PRTG N/A
- Revenue This Year
- SGLY N/A
- PRTG N/A
- Revenue Next Year
- SGLY N/A
- PRTG N/A
- P/E Ratio
- SGLY N/A
- PRTG N/A
- Revenue Growth
- SGLY N/A
- PRTG N/A
- 52 Week Low
- SGLY $1.27
- PRTG $2.10
- 52 Week High
- SGLY $7.65
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- SGLY 57.89
- PRTG 42.98
- Support Level
- SGLY $1.98
- PRTG $4.01
- Resistance Level
- SGLY $5.49
- PRTG $4.40
- Average True Range (ATR)
- SGLY 0.57
- PRTG 0.43
- MACD
- SGLY 0.12
- PRTG -0.09
- Stochastic Oscillator
- SGLY 29.20
- PRTG 12.34
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.